Orchid Pharma has purchased land situated at Patibulum Village, Kancheepuram District, Tamil Nadu. This acquisition concludes the company's lease arrangement with DBS Bank India Limited and secures permanent ownership of the property.

The transaction marks the cessation of DBS Bank's rights and interest in the said property. The move provides certainty and clarity regarding the company's ownership status of the asset.

Regulatory Disclosure

The company filed an intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015. The disclosure references an earlier intimation dated June 6, 2025, which concerned the disposal of a dispute related to the lease rental of the subject property.

Transaction Details

The purchase resolves the prior lease structure entirely. Key aspects of the development include:

• Location: Patibulum Village, Kancheepuram District, Tamil Nadu
• Counterparty: DBS Bank India Limited
• Outcome: Permanent closure of the lease arrangement
• Status: Full ownership rights vested in Orchid Pharma

Orchid Pharma has scheduled an investor roadshow in Mumbai from September 28 to 30, 2026. The company announced the event in a filing with the National Stock Exchange of India Limited and BSE Limited on September 21, 2026.

Mridul Dhanuka, Whole Time Director of the company, will participate in the meetings. The roadshow is structured as a series of physical group meets.

Roadshow Schedule

The company outlined the specific dates and format for the upcoming engagement with investors.

The company noted that the schedule may change due to unforeseen exigencies on the part of investors or the company. Any changes will be communicated if they occur.

Regulatory Disclosure

The intimation was issued pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Kapil Dayya, Company Secretary and Compliance Officer, signed the filing. He confirmed that no Unpublished Price Sensitive Information is proposed to be shared during the investor meet.